PT  - JOURNAL ARTICLE
AU  - TANIGUCHI, YOSHIE
AU  - NISHIZAWA, TAKASHI
AU  - HONDA, TERUKO
AU  - YOSHIOKA, NORIKO
AU  - INAGAWA, HIROYUKI
AU  - KOHCHI, CHIE
AU  - SOMA, GEN-ICHIRO
TI  - Development and Potential Use of a Monoclonal Antibody to the Lipopolysaccharide of <em>Pantoea agglomerans</em> (IP-PA1)
DP  - 2007 Nov 01
TA  - Anticancer Research
PG  - 3701--3706
VI  - 27
IP  - 6A
4099  - http://ar.iiarjournals.org/content/27/6A/3701.short
4100  - http://ar.iiarjournals.org/content/27/6A/3701.full
SO  - Anticancer Res2007 Nov 01; 27
AB  - Background: The lipopolysaccharide of Pantoea agglomerans (IP-PA1) has been shown to be effective and safe in the prevention of various diseases, such as bacterial or viral infection, lifestyle-related diseases, when administered transdermally or orally. To clarify the mechanisms of the preventive or therapeutic effect induced by IP-PA1, we tried to establish a monoclonal antibody to detect IP-PA1. The enzyme-linked immunosorbent assay (ELISA) was used to measure the amount of IP-PA1. Materials and Methods: Antibodies were raised by immunization using heat-killed Pantoea agglomerans and screening was conducted to isolate monoclonal antibodies specific to IP-PA1. Results: Six kinds of IP-PA1 specific monoclonal antibodies with different epitopes were established. An ELISA using the monoclonal antibodies was successfully established which could specifically detect IP-PA1. Conclusion: By use of this ELISA, the staple food content and pharmacodynamic analysis of IP-PA1 could be conveniently estimated. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved